Primary SARS-CoV-2 variant of concern infections elicit broad antibody Fc-mediated effector functions and memory B cell responses
Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by human sera is a strong correlate of protection against symptomatic and severe Coronavirus Disease 2019 (COVID-19). The emergence of antigenically distinct SARS-CoV-2 variants of concern (VOCs) and the relatively rapid waning of serum antibody titers, however, raises questions about the sustainability of serum protection. In addition to serum neutralization, other antibody functionalities and the memory B cell (MBC) response are suggested to help maintaining this protection. In this study, we investigate the breadth of spike (S) protein-specific serum antibodies that mediate effector functions by interacting with Fc-gamma receptor IIa (FcγRIIa) and FcγRIIIa, and of the receptor binding domain (RBD)-specific MBCs, following a primary SARS-CoV-2 infection with the D614G, Alpha, Beta, Gamma, Delta, Omicron BA.1 or BA.2 variant. Irrespectively of the variant causing the infection, the breadth of S protein-specific serum antibodies that interact with FcγRIIa and FcγRIIIa and the RBD-specific MBC responses exceeded the breadth of serum neutralization, although the Alpha-induced B cell response seemed more strain-specific. Between VOC groups, both quantitative and qualitative differences in the immune responses were observed, suggesting differences in immunogenicity. Overall, this study contributes to the understanding of protective humoral and B cell responses in the light of emerging antigenically distinct VOCs, and highlights the need to study the immune system beyond serum neutralization to gain a better understanding of the protection against emerging variants.
Authors
- Denise Guerra (ORCID: https://orcid.org/0000-0003-4493-7885)
- Steven W. de Taeye (ORCID: https://orcid.org/0000-0001-7915-9230)
- Marit J. van Gils (ORCID: https://orcid.org/0000-0003-3422-8161)
- Anders C. Boyd (ORCID: https://orcid.org/0000-0001-9512-8928)
- Jacqueline van Rijswijk
- Tim Beaumont (ORCID: https://orcid.org/0000-0002-0778-8027)
- Godelieve J. de Bree (ORCID: https://orcid.org/0000-0002-5852-5833)
- Marloes Grobben (ORCID: https://orcid.org/0000-0002-1559-9592)
- Mathieu Claireaux (ORCID: https://orcid.org/0000-0003-1890-9493)
- Gius Kerster (ORCID: https://orcid.org/0000-0001-6880-7351)
- Angela I. Schriek
- Dirk Eggink (ORCID: https://orcid.org/0000-0002-4248-6008)
- Rogier W. Sanders (ORCID: https://orcid.org/0000-0002-2324-8573)
- Karlijn van der Straten
- Khadija Tejjani
Institutions
- Cornell University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- National Institute for Public Health and the Environment (NL)
- Stichting HIV Monitoring (NL)
- GGD Amsterdam (NL)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- PLoS Pathogens
- Published
- 2024-08-15
- DOI
- https://doi.org/10.1371/journal.ppat.1012453
- Citations
- 3
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- Bill and Melinda Gates Foundation
- Amsterdam University Medical Centers
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek
- Rijksinstituut voor Volksgezondheid en Milieu